NMN’s safety profile is one of its stronger selling points, but honesty requires distinguishing between what has been tested and what has not. Here is what the clinical trial data actually shows.
What Clinical Trials Report
Phase 1 Safety Data
The first human safety study administered single oral doses of 100, 250, and 500 mg NMN to 10 healthy Japanese men. No significant clinical symptoms were observed. Heart rate, blood pressure, oxygen saturation, and body temperature remained stable. Laboratory tests showed no significant abnormalities, with only minor fluctuations in serum bilirubin, creatinine, and blood glucose that stayed within normal ranges (Irie et al., 2020).
12-Week Safety Data
A placebo-controlled trial gave 15 healthy adults 250 mg/day NMN for 12 weeks. No abnormalities were found in physiological or laboratory tests, and no obvious adverse effects were observed (Okabe et al., 2022).
Dose-Dependent Safety
The Yi et al. multicenter trial tested 300, 600, and 900 mg/day in 80 adults for 60 days. All 80 participants completed the trial without protocol violations, and no safety issues were identified based on adverse event monitoring, laboratory measures, or clinical assessment (Yi et al., 2023).
High-Dose Safety
The MIB-626 program tested pharmaceutical-grade NMN at 1,000 mg once or twice daily. At 1,000 mg daily for 14 days, the frequency of adverse events was similar between NMN and placebo groups (Pencina et al., 2022). At 2,000 mg daily (1,000 mg twice) for 28 days, adverse events were again similar between groups (Pencina et al., 2023).
Known Side Effects
Common (Reported by Multiple Users)
- Mild digestive discomfort: Nausea, gas, bloating, or abdominal discomfort, particularly during the first few days of supplementation or at higher doses. These effects are consistent with other NAD+ precursors like NR.
- Headaches: Occasional mild headaches, typically transient and resolving within the first week.
Less Common
- Insomnia or sleep disturbance: Some users report difficulty falling asleep, especially when taking NMN in the evening. This may relate to NAD+‘s role in circadian rhythm regulation.
- Upper respiratory symptoms: Reported in some studies as a general side effect category, though causality is uncertain.
Not Observed in Trials
Serious adverse events, liver toxicity, kidney damage, or cardiovascular problems have not been reported in any published NMN human trial at studied doses.
The Long-Term Safety Gap
This is the most important caveat. The longest published human trial of NMN supplementation is 12 weeks. Most trials are 4-10 weeks. No one has published safety data from 6 months, 1 year, or longer of continuous human NMN use.
The 12-month mouse study by Mills et al. found no toxicity or deleterious effects from chronic NMN administration (Mills et al., 2016). Animal toxicology studies established a No-Observed-Adverse-Effect-Level (NOAEL) ranging from 500-1,500 mg/kg/day in rats, which extrapolates to a wide safety margin at human supplement doses.
These animal data are reassuring but not definitive. If you plan to take NMN for extended periods, periodic bloodwork and physician check-ins are reasonable precautions.
Populations Who Should Exercise Caution
Cancer Patients
NAD+ supports cellular energy production and DNA repair in all cells, including potentially cancerous ones. Some researchers have raised theoretical concerns that boosting NAD+ could support cancer cell metabolism. No human evidence directly links NMN supplementation to cancer promotion or progression, but the theoretical risk has not been ruled out. Individuals with active cancer or a history of cancer should consult their oncologist before taking NMN.
Pregnant or Breastfeeding Women
No safety data exists for NMN use during pregnancy or lactation. In the absence of data, avoidance is the standard recommendation.
People with Liver or Kidney Disease
NMN is metabolized and its metabolites are excreted through standard hepatic and renal pathways. Impaired liver or kidney function could theoretically alter NMN metabolism. No trials have been conducted specifically in these populations. Consult your physician.
People on Blood Pressure or Cholesterol Medications
The Pencina et al. (2023) study found that high-dose NMN reduced blood pressure and cholesterol levels. If you are already taking antihypertensives or statins, adding NMN could theoretically produce additive effects. Monitor your levels and discuss with your prescribing physician.
Children and Adolescents
No NMN trials have been conducted in individuals under 18. NMN supplementation is not recommended for this population.
Drug Interactions
Formal drug interaction studies for NMN have not been published. Based on NMN’s mechanism of action and metabolic pathway, potential interactions to be aware of include:
- NAD+-modulating drugs: Medications that affect NAD+ metabolism (such as certain chemotherapeutics that target PARP or NAMPT) could interact with NMN supplementation.
- Diabetes medications: Given NMN’s demonstrated effect on insulin sensitivity, combining NMN with metformin or insulin could theoretically alter glucose dynamics. This is speculative but worth monitoring.
- Blood pressure medications: As noted above, high-dose NMN has shown blood pressure-lowering effects.
Until formal interaction studies are published, inform your physician about NMN use if you take any prescription medications.
NMN vs. NR Safety Comparison
NR (nicotinamide riboside) has a longer human safety track record with more published data. Both compounds share a similar side effect profile (mild GI effects, headaches). Neither has demonstrated serious adverse events in clinical trials. The safety profiles appear comparable based on available data.
References
-
Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153-160. PMID: 31685720
-
Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640. PMID: 35479740
-
Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults. Geroscience. 2023;45(1):29-43. PMID: 36482258
-
Pencina KM, Lavu S, Dos Santos M, et al. MIB-626 increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2023;78(1):90-96. PMID: 35182418
-
Pencina KM, Valderrabano R, Wipper B, et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PMID: 36740954
-
Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. PMID: 28068222